CORC

在结果中检索

CORC

浏览/检索结果: 共36条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy 期刊论文
FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 卷号: 9
作者:  Yuan, Meiqin;  Wang, Zeng;  Lv, Wangxia;  Pan, Hongming
收藏  |  浏览/下载：20/0  |  提交时间：2022/05/16
Integrative Gene Expression Profiling Analysis to Investigate Potential Prognostic Biomarkers for Colorectal Cancer 期刊论文
MEDICAL SCIENCE MONITOR, 2020, 卷号: 26, 页码: 14
作者:  Liu, Xinkui;  Bing, Zhitong;  Wu, Jiarui;  Zhang, Jingyuan;  Zhou, Wei
收藏  |  浏览/下载：39/0  |  提交时间：2022/01/19
Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study 期刊论文
FUTURE ONCOLOGY, 2018, 卷号: 14, 期号: 20
作者:  Li, Jin;  Xu, Ruihua;  Qin, Shukui;  Liu, Tianshu;  Pan, Hongming
收藏  |  浏览/下载：7/0  |  提交时间：2019/12/05
Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study 期刊论文
FUTURE ONCOLOGY, 2018, 卷号: Vol.14 No.20, 页码: 2030-2043
作者:  Li, Jin;  Xu, Ruihua;  Qin, Shukui;  Liu, Tianshu;  Pan, Hongming
收藏  |  浏览/下载：4/0  |  提交时间：2019/02/25
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis 期刊论文
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 卷号: Vol.48 No.5, 页码: 1870-1881
作者:  Shui, Lin;  Wu, Yu-Shen;  Lin, Huapeng;  Shui, Pixian;  Sun, Qin
收藏  |  浏览/下载：4/0  |  提交时间：2019/02/25
Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1*28 and*6 wild type and its implication for individualized chemotherapy 期刊论文
CANCER BIOLOGY & THERAPY, 2017, 卷号: 18, 期号: 3
作者:  Cai, Xun;  Tian, Chuan;  Wang, Liwei;  Zhuang, Rongyuan;  Zhang, Xiaowei
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/05
FOLFIRI Regimen with or without Bevacizumab as Second-Line Therapy Showed Activity in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma 会议论文
作者:  Chen, Z.;  Zhao, X.;  Wang, C.;  Zhang, W.;  Zhu, X.
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/05
Preliminary analysis of FOLFIRI regimen with or without bevacizumab as second-line systemic therapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma. 会议论文
作者:  Zhao, Xiaoying;  Wang, Chen Chen;  Zhang, Wen;  Zhu, Xiaodong;  Guo, Weijian
收藏  |  浏览/下载：6/0  |  提交时间：2019/12/05
A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer 期刊论文
BMC CANCER, 2017, 卷号: 17
作者:  Liu, Xin;  Guo, Weijian;  Zhang, Wen;  Yin, Jiliang;  Zhang, Jun
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/05
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study 期刊论文
CLINICAL COLORECTAL CANCER, 2017, 卷号: 16, 期号: 2, 页码: E73-E88
作者:  Cheng, Ann-Lii;  Cornelio, Gerardo;  Shen, Lin;  Price, Timothy;  Yang, Tsai-Sheng
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/12

©版权所有 ©2017 CSpace - Powered by CSpace